180 Life Sciences Corp. (ATNF)
0.85
-0.03 (-3.41%)
At close: Apr 04, 2025, 12:35 PM
-3.41% (1D)
| Bid | 0.83 |
| Market Cap | 4.43M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | 7.98 |
| PE Ratio (ttm) | 0.11 |
| Forward PE | -3.2 |
| Analyst | n/a |
| Ask | 0.88 |
| Volume | 12,660 |
| Avg. Volume (20D) | 110,818 |
| Open | 0.85 |
| Previous Close | 0.88 |
| Day's Range | 0.83 - 0.87 |
| 52-Week Range | 0.83 - 17.75 |
| Beta | 0.21 |
About ATNF
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials t...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 27, 2017
Employees 4
Stock Exchange NASDAQ
Ticker Symbol ATNF
Website https://180lifesciences.com
3 months ago
-24.03%
180 Life Sciences Corp. shares are trading lower a...
Unlock content with
Pro Subscription
5 months ago
+9.79%
180 Life Sciences shares are trading higher after Elray Resources completed a sale of proprietary technology to the company to assist in the launch of an iGaming Blockchain casino.
2 years ago · businesswire.com
Elicit Plant beruft Pam Marrone und Johan de Saegher in den VorstandMOULINS-SUR-TARDOIRE, Frankreich--(BUSINESS WIRE)--Elicit Plant, ein Agro-Biotechnologieunternehmen, das sich auf die Resistenz von Nutzpflanzen gegen Wasserstress auf Basis einer phytosterolbasierten...
